Clinical Trial Update: A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated three different doses of VAC52416 (ExPEC10V) in adults aged 60–85 to assess safety and immunogenicity for preventing extraintestinal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extraintestinal Pathogenic Escherichia Coli Infection

Drugs mentioned

• ExPEC10V (VAC52416)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Extraintestinal Pathogenic Escherichia Coli Prevention | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-25